Loading clinical trials...

COMPLETED

HIV Treatment-Readiness Measure (HTRM) Validation

Validation of the HIV Treatment Readiness Measure (HTRM)

NCT00686049•University of North Carolina, Chapel Hill

Summary

The goal of this study is to assess the reliability of the HIV Treatment Readiness Measure (HTRM) to assist clinicians in: (1) determining whether or not youth living with HIV are ready to initiate HAART and (2) identifying youth who may be in need of additional support services to facilitate their adherence to HAART. The current study will examine the psychometric properties of the HTRM and establish its test-retest reliability over a two week period. If the HTRM is found to be reliable, a subsequent study will examine its predictive validity.

Eligibility

Age

13 - 24 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•HIV-positive youth, 13 years 0 days to 24 years 364 days of age
•Either HAART naïve (defined as never having taken HAART) or HAART experienced (defined as having had at least one experience taking HAART and not having taken HAART for 30 days prior to study entry)
•Not currently on HAART, but planning to initiate HAART within the next 2 months based on provider recommendation
•Enrolled in care at an AMTU or a collaborating site
•Able to speak and understand English
•Willing to provide informed consent, or assent with parental permission (if required by the site IRB) for participation in this study.

Exclusion Criteria

•Evidence of cognitive impairment or other mental condition that limits his/her ability to complete the assessment (per PI or designee discretion)
•Determined by the PI (or designee) to be under the influence of psychoactive agents or intoxicated at the time of assessment to a degree that would interfere with successful completion of the questionnaire
•Visibly distraught or unstable
•Any clinical condition that would likely interfere with the participant's ability to complete the study
•Participants who are unable to speak English will be excluded from the initial testing of the HTRM's reliability and validity in keeping with traditional tool development strategies. If the initial study indicates that the English version of the HTRM is reliable and valid, appropriate methods will be employed to translate the instrument into Spanish and the reliability and validity will be re-examined for the Spanish version.

Locations (15)

Childrens Hospital of Los Angeles

Los Angeles, California, United States

University of California San Francisco

San Francisco, California, United States

Childrens National Medical Center

Washington D.C., District of Columbia, United States

Childrens Diagnostic & Treatment Center, Inc

Fort Lauderdale, Florida, United States

University of Miami School of Medicine

Miami, Florida, United States

USF College of Medicine

Tampa, Florida, United States

Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital

Chicago, Illinois, United States

Childrens Memorial Hospital

Chicago, Illinois, United States

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

University of Maryland Express Mailing Address:

Baltimore, Maryland, United States

Key Dates

Start Date

May 1, 2008

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

February 28, 2017

Enrollment

200

ACTUAL participants

Conditions

HIV Infections

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITINGPHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

HIV Treatment-Readiness Measure (HTRM) Validation

Inclusion Criteria

Exclusion Criteria

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Comprehensive HIV and Harm Prevention Via Telehealth